Glioblastoma Therapeutics

Trending

View All

Jul 19, 2022

Byondis’s HER2-targeting ADC trastuzumab duocarmazine; AbbVie Migraine Drug Atogepant; Grünenthal Acquires Bayer’s Testosterone Drug Rights; Vertex Acquires ViaCyte; Merck & Orion Announces Collaboration; Verve Starts Trials of Cholesterol Drug; Kyowa Kirin Drops Nourianz follow-up KW-6356; FDA Orphan Drug and Fast Track Designations to CV-01

Byondis Files its HER2-Targeting Antibody-Drug Conjugate (ADC) Trastuzumab Duocarmazine in the US and Europe Byondis has filed for clearance of its HER2-targeting antibody-drug conjugate (ADC) trastuzumab duocarmazine in the United States and Europe, setting up a battle with heavyweight competitors Roche and Ast...

Find More

Editor's Pick

Wainua – The Only Approved Medicine for hATTR-PN Treatment

lyfgenia-or-casgevy-for-sickle-cell-disease-treatment

Lyfgenia or Casgevy: Who Will Lead the Sickle Cell Disease Treatment Space?

Another Feather in the Cap for Xtandi and Keytruda — The Two Main Cancer Drugs

vabysmo-for-retinal-vein-occlusion-treatment

Roche’s Vabysmo Third US Approval Spiced Up the Battle With Regeneron and Bayer’s Eylea

AAV Gene Therapies for Hemophilia B Treatment: The Road to a Cure

Newsletter/Whitepaper

ASCO Conference 2023

The American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.

Catch the Glimpse here

By DelveInsight

Glioblastoma Therapeutics

Search by Categories

Our expertise in the industry

View All

Editor's Pick

Newsletter/Whitepaper

ASCO Conference 2023